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OBJECTIVES We set out to determine the effect of sustained treatment with nitroglycerin (GTN) on neural
modulation of heart rate in humans.
BACKGROUND Acutely, exogenous and endogenous nitric oxide reduces sympathetic, while increasing vagal,
outflow. An animal study showed loss of these effects during nitrate tolerance.
METHODS A total of 29 healthy men (age range, 18 to 32 years) received transdermal GTN
(0.6 mg/h/24 h) or no therapy for six days in a parallel controlled trial. The reflex regulation
of heart rate was assessed with the spontaneous baroreflex sensitivity (BRS) method. Heart
rate variability was calculated both in time (standard deviation of mean RR interval [RRSD])
and frequency domains (Fast Fourier Transformation) over 10-min intervals.
RESULTS Systolic blood pressure was unchanged after continuous GTN, whereas mean RR interval
decreased significantly (from 839 to 781 ms, p  0.05). Nitroglycerin blunted BRS (p 
0.05). When compared with untreated subjects, RRSD was significantly lower after GTN,
whereas the ratio of low to high frequencies was increased (all p  0.05).
CONCLUSIONS Chronic GTN reduces tonic and reflex vagal heart rate modulation, resulting in greater
relative sympathetic influence. Importantly, such changes in the regulation of chronotropic
oscillations might have negative prognostic implications in both heart failure and coronary
artery disease. Furthermore, because chronic GTN alters the blood pressure/heart rate
relationship, our data suggest caution when using these variables as pharmacodynamic
markers for the development of nitrate tolerance. (J Am Coll Cardiol 2002;40:2000–5)
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Nitroglycerin (GTN) and other nitric oxide (NO) donors
are commonly used vasodilators. Sustained administration
of GTN can cause generalized neurohormonal activation,
including an increase in plasma norepinephrine, renin,
arginine vasopressin, and aldosterone levels (1,2). Although
these responses were initially considered one mechanism of
nitrate tolerance (1), this link has yet to be definitively
established. Nevertheless, it does appear that chronic nitrate
therapy can alter the function of the autonomic nervous
system.
Interactions between vascular and autonomic effects of
NO donors are complex. When nitrovasodilators, including
organic nitrates, are given systemically, the reduction in
arterial blood pressure acts as a reflex stimulus to sympa-
thetic outflow (3). However, at the same time, the acute
administration of these NO donors also exerts sympatho-
inhibitory actions at multiple central and peripheral sites,
and augments efferent vagal tone (4–10). Interpretation of
autonomic responses to NO donors is further complicated
by the fact that their direct acute effects on the autonomic
nervous system might not be sustained during chronic
therapy. For example, evidence from a porcine model
suggests that long-term nitrate therapy causes a loss of this
central sympathoinhibitory effect of NO and is associated
with more pronounced increases in sympathetic outflow in
response to stimulation (10). The purpose of the present
experiment was to determine the impact of continuous
nitrate therapy on parameters of the modulation of heart
rate such as heart rate variability (HRV) and baroreflex
sensitivity (BRS) in healthy humans.
METHODS
Study population. Twenty-nine healthy men (age range,
18 to 32 years) participated. All subjects abstained from
caffeine and physical exercise on study days and from any
drug, including supplemental vitamins, for the duration of
these investigations. Exclusion criteria included hyper- or
hypotension, concurrent illness, use of medications, and
smoking. The University of Toronto Human Subjects
Review Committee approved the study protocol, and writ-
ten informed consent was obtained from all volunteers.
Measurement of spontaneous baroreflex and short-term
HRV. Studies occurred at the same time of the day.
Subjects sat in a quiet, temperature- and humidity-
controlled environment for 10 min before measurements
were obtained. A finger cuff was placed on the right medium
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finger for continuous noninvasive beat-to-beat recording of
blood pressure (Ohmeda 2300 Finapres, Rexdale, Ontario,
Canada). Subjects were instructed to breathe regularly at a
frequency of 0.2 Hz. Blood pressure and heart rate (lead II
of the electrocardiogram) were recorded continuously for
10 min, acquired digitally at a frequency of 1,000 Hz, and
stored into disk using a Labview-based software for subse-
quent analysis (11). All subjects were in sinus rhythm, and
measurement periods excluded any extrasystoles. The stan-
dard deviation of RR intervals (RRSD) was calculated for
each subject as a time domain index of tonic overall
short-term HRV. The RRSD is also considered a prognos-
tic indicator in patients with heart disease, although, for this
purpose, longer time intervals (i.e., 24 h) have generally
been used. The utility of shorter measurement periods, such
as those utilized in the present study as prognostic indica-
tors, remains controversial. Spontaneous BRS was assessed
to determine reflex vagal control, using previously reported
methods (12). Briefly, sequences of three or more beats,
during which systolic blood pressure and the RR interval of
the immediately following beat changed in parallel, were
isolated, identified, and categorized as either up sequences
(rising systolic blood pressure and RR interval) or down
sequences (decreasing systolic blood pressure and RR inter-
val). For each study day and subject, the mean value of the
slope (gain) of these relationships, that is, the change in
millisecond of RR interval per mm Hg change in systolic
blood pressure, was calculated separately for both up and
down sequences. This method reliably estimates the gain of
the baroreflex control of heart rate at physiologic levels of
arterial blood pressure (13). Because of the rapidity with
which they occur, these heart rate responses to spontaneous
rises and falls in blood pressure are felt to be mediated,
respectively, by phasic vagal cholinergic activation and vagal
withdrawal (14).
In addition, for each measurement period, the analog
output of the electrocardiogram amplifier was stored for
spectral analysis by Fast Fourier Transformation. Details of
this technique have been reported elsewhere (11). Low-
frequency harmonic (LF) (0.05 to 0.15 Hz) and high-
frequency harmonic (HF) (0.15 to 0.50 Hz) components of
spectral power were calculated. High-frequency compo-
nents can be considered, after normalization, an index of
parasympathetic nervous system activity (15,16). High fre-
quency was expressed in normalized units as obtained by
dividing the absolute power of this HF over the power
within 0.05 and 0.5 Hz (HF  LF) and multiplying by 100
(HFnu) (15,16). At rest, heart rate is influenced mostly by
vagal modulation, but a constant, reciprocal interaction
between vagal and sympathetic activity also exists (15). The
LF/HF ratio has been proposed as a model to estimate the
reciprocal changes of sympathetic and parasympathetic neu-
ral contributions to heart rate modulation (sympathovagal
balance) (15,16), even if this interpretation has been criti-
cized (17).
Study protocol. The study was designed as an open-label,
parallel, controlled trial. Two groups of subjects were
studied. The GTN group comprised 15 volunteers. On visit
1, after acquisition of baseline values (pretreatment), the
first dose of GTN was administered in the form of a 0.6
mg/h transdermal patch (Transderm Nitro, Novartis, Dor-
val, Quebec, Canada). Subjects were then given a six-day
supply of transdermal GTN and were instructed to wear
each patch continuously over 24 h and replace it with a new
one every morning at 9 AM. On visit 2, after six days of
continuous GTN therapy, posttreatment data were ac-
quired. Fourteen additional volunteers were recruited to
undergo a measurement of BRS and HRV at baseline and
after one week. Subjects in this control group were not
treated with transdermal GTN, but underwent the same
measurement protocols. The computer files containing the
data recorded on visit 1 and visit 2 for each volunteer in both
groups were assigned a code and subsequently analyzed at
the end of the study. The investigator responsible for all
analysis was blinded to the coding system.
Statistical analysis. Results for BRS were not normally
distributed. A Wilcoxon signed rank test was used to
compare BRS slopes between visits within the GTN group.
A paired t test was used to compare all other predetermined
variables of interest before and after treatment within
groups. For comparisons between groups, analysis of covari-
ance (ANCOVA) was used. For this analysis, BRS data
were logarithmically transformed. A value of p  0.05 was
set as the threshold for significance. All results are expressed
as mean  SE unless otherwise noted. Statview (SAS
Institute Inc., SAS Campus Drive, Cary, North Carolina)
was employed for all statistical analyses.
RESULTS
Baseline values. There were no differences between the
GTN and control groups with respect to mean values of age,
baseline blood pressure, BRS during both up and down
sequences, RRSD, and parameters of sympathetic and
parasympathetic nervous activity (Tables 1 and 2). No
significant difference was found in the number of baroreflex
sequences per minute per heart rate either between the two
groups or between visits within each group.
Abbreviations and Acronyms
ANCOVA  analysis of covariance
BRS  baroreflex sensitivity
GTN  nitroglycerin
HFnu  high-frequency components of spectral
analysis (normalized units)
HRV  heart rate variability
LF  low-frequency components of spectral
analysis
LF/HF  ratio of low- to high-frequency
components
NO  nitric oxide
RRSD  standard deviation of RR intervals
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Effect of GTN on BRS. In the control group, no signif-
icant change was observed for any measured value on visit 2
compared with visit 1 (Table 1). In the GTN group, systolic
blood pressure was unchanged after sustained treatment. As
well, there was no significant difference between visits in
mean blood pressure (visit 1: 88  2; visit 2: 90  3 mm
Hg). However, in this group, the RR interval was signifi-
cantly reduced on visit 2 (p  0.05, Table 2). Continuous
treatment with transdermal GTN caused a significant re-
duction in the sensitivity of the spontaneous baroreceptor
reflex. In particular, the slopes of up sequences were
significantly lower on visit 2 as compared with visit 1 (p 
0.01) (Table 1, Fig. 1), while those for down sequences were
also lower, although not significantly so (p  0.1). The
ANCOVA revealed that the overall differences between
groups in RR interval and BRS (including both up and
down sequences) were significant (p  0.05).
Effect of GTN on short-term HRV. Heart rate variability
results are presented in Table 2 and Figure 2. The sum of
HF and LF power was not changed after GTN treatment.
There was a nonsignificant trend for lower HFnu on visit 2
as compared with visit 1 in the GTN group (p  0.1).
Analogous results were obtained with time domain markers
of vagally mediated HRV such as pNN50 (number of
differences of successive RR intervals greater than 50 ms
divided by the total number of intervals, data not presented).
Importantly, ANCOVA revealed a significant decrease in
RRSD and increase in LF/HF at the end of the treatment
with GTN when compared with the control group (p 
0.05).
DISCUSSION
Findings of the study. In this study of the effect of
continuous therapy with GTN, systolic and mean blood
pressures were similar on visits 1 and 2 in both untreated
and treated subjects, confirming that sustained therapy has
no impact on this variable. Although not studied here,
previous experiments have demonstrated that acute appli-
cation of this formulation of transdermal GTN has a
Table 1. Blood Pressure and Heart Rate at Baseline and After Transdermal GTN or No Treatment
Visit 1 Visit 2
Systolic blood pressure, mm Hg
Control group 112  2 113  1
GTN group 112  3 115  2
Up Down Up Down
BRS, ms/mm Hg
Control group 10.0  1.2 (8.0) 10.2  1.1 (8.8) 10.8  1.4 (10.1) 10.1  1.3 (10.5)
GTN group 12.2  1.4 (11.4) 11.6  1.4 (12.0) 8.1  0.8 (9.5)* 8.8  0.8 (9.0)
BRS data are presented as mean  SE (median). *p  0.01, Wilcoxon signed rank test.
BRS  baroreflex sensitivity; GTN  nitroglycerin.
Table 2. RR Interval and Heart Rate Variability at Baseline and
After Treatment With Transdermal GTN or No Therapy
Visit 1 Visit 2
RR interval, ms
Control group 822  22 839  32
GTN group 839  13 781  13*
LF and HF, ms2
Control group
LF 1,828  475 1,758  406
HF 807  187 839  218
GTN group
LF 1,589  403 1,844  435
HF 924  336 478  116
LF/HF
Control group 2.58  0.39 2.48  0.31
GTN group 2.85  0.61 4.87  0.81*
HFnu, normalized
units
Control group 32  4 31  2
GTN group 33  5 22  4
*p  0.05 compared with control group, analysis of covariance.
GTN  nitroglycerin; HF  high-frequency components of spectral analysis;
LF  low-frequency components of spectral analysis.
Figure 1. The effect of nitroglycerin (GTN) treatment on baroreflex
sensitivity. The slopes of the relationship between spontaneous changes in
systolic blood pressure (SBP) and reflex changes in the immediately
following RR interval are presented. Up sequences are presented in the
upper panel, while down sequences are presented in the lower panel.
Pretreatment values (visit 1, solid lines) are compared with post-GTN
treatment (visit 2, dashed lines). Thick lines represent the median value
for the group on each visit; thinner lines represent the interquartile range.
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significant effect on blood pressure (1,18), and the loss of
this initial hypotensive response has been repeatedly re-
ported as evidence of the occurrence of GTN tolerance
(1,18). While this hypotensive effect of GTN disappeared
after continuous treatment with GTN, heart rate tended to
remain higher (18,19). This observation was confirmed in
our study, in that a significant difference between baseline
RR interval and that recorded during treatment in visit 2
was observed.
The neural mechanisms for the dissociation of heart rate
and blood pressure effects during chronic GTN therapy
have not been established. In the present experiment, GTN
therapy was associated with a significant decrease in the
sensitivity of the baroreflex vagal control of heart rate.
Because blood pressure was not different after prolonged
GTN treatment, the described decrease in BRS cannot be
attributed to any change in the operating set point of the
reflex. In addition, the ratio LF/HF was increased. This
parameter is considered, by some investigators (15), a
frequency domain representative of the relative balance
between sympathetic and parasympathetic modulatory in-
fluence on the variability of heart rate, although this
approach has been criticized (17,20). Finally, a significant
reduction in short-term RRSD was observed. Taken to-
gether, these changes are compatible with an overall increase
in sympathetic, and a parallel withdrawal in parasympa-
thetic, modulation of chronotropic oscillations. Impor-
tantly, such alterations in autonomic control of heart rate
have been associated with increased incidence of arrhyth-
mias and worse prognosis in patients with coronary artery
disease and/or heart failure (21,22). Because these two
conditions also represent the major indications for nitrate
use, the potential implications of these observations for
clinical practice should be considered.
Possible mechanisms involved. Nitroglycerin may exert
these effects through a number of direct and indirect
mechanisms on autonomic outflow. In a study in rabbits,
acute NO infusion into isolated carotid sinuses caused a
significant inhibition of baroreceptor nerve discharge in
response to pressure ramps, suggesting an afferent inhibitory
mechanism independent of any hemodynamic and/or direct
central effect of NO (23). In our model, diminished barore-
ceptor impact on central integration might have caused a
decrease in efferent vagal discharge, while also decreasing
the restraining influence of the baroreceptors on outflow
from the central sympathetic oscillations. Such interpreta-
tion appears unlikely given that this effect on baroreceptor
discharge only occurs with local concentrations of NO
donors that are higher than those reached during transder-
mal therapy (24). At the efferent limb, the demonstrated
direct positive chronotropic effect of nitrovasodilators might
also have contributed to our observed decrease in RR
interval after GTN treatment (25). Finally, the possibility of
the persistence of a hemodynamic effect of GTN resulting
in reflex sympathetic activation, despite the absence of an
effect on systolic and mean blood pressure measured from
the brachial artery, has to be considered. For example, the
effect of organic nitrates on aortic blood pressure might be
more pronounced than at the level of the upper limb (26),
leading to a reflex increase in sympathetic outflow.
Central actions of GTN should also be considered. Both
animal and human studies have demonstrated an important,
physiologic neuromodulator effect mediated by NO synthe-
sis in the central nervous system, resulting in a net increase
in parasympathetic and decrease of sympathetic activity (9).
Importantly, these effects of NO appear to be lost in the
setting of sustained nitrate treatment and tolerance. In
animal studies, after induction of tolerance, a marked
enhancement in sympathetic outflow in response to gluta-
mate infusion and electric stimulation of somatic nerve
efferents was demonstrated (10,19). Zanzinger et al. (10)
hypothesized that this abnormality is caused by reduction of
endogenous NO synthesis as a result of continuous treat-
ment with an organic nitrate. In support of this hypothesis,
Figure 2. Left: Overall (up and down sequences) baroreflex sensitivity (BRS) before and after treatment with transdermal nitroglycerin (GTN) or no
therapy in the two groups. Right: Corresponding changes in SD of RR intervals (RRSD) in the two groups. Dashed lines  control group; solid lines 
GTN group; empty circles  visit 1; solid circles  visit 2. *p  0.05; analysis of covariance (GTN vs. control group).
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the authors pointed out that sustained nitrate treatment
impaired NO production in the lower brain stem, thus
causing subsequent loss of the NO-mediated sympathoin-
hibitory mechanism (10). Interestingly, this process would
be analogous to the abnormalities in vascular endothelial
NO synthase function observed in our laboratory in the
same experimental model of nitrate tolerance (18).
In the present study, sympathetic activity was not mea-
sured directly (by measurements of muscle sympathetic
activity or cardiac norepinephrine spillover), thus, we cannot
conclude definitively that sympathetic modulation of heart
rate was increased in absolute terms. Furthermore, the
analysis of HRV, while allowing reliable investigation of
vagal control, provides less information on sympathetic
outflow. The reduction in BRS and RRSD and the increase
in LF/HF after treatment with GTN might be an expres-
sion of the described loss of inhibitory modulation of the
sympathetic nervous system by endogenous NO. However,
whether the observed changes were due to unmasking of
underlying sympathetic modulation by a decrease in vagal
tone, a direct inhibitory effect of increased cardiac sympa-
thetic nerve traffic on parasympathetic modulation of heart
rate (27), or both, cannot be established definitively from
the available data.
Implications for the assessment of nitrate tolerance. An
implication of our results is that blood pressure and heart
rate measurements should be used with caution as markers
of nitrate tolerance. The loss of blood-pressure-lowering
effects of GTN during sustained therapy might be medi-
ated, at least in part, by sympathovagal imbalance (“sympa-
thetic” tolerance) (10,19). Nitrate tolerance is a complex,
multifaceted process that involves nervous, neurohormonal,
and local vascular abnormalities. Changes in autonomic
regulation during chronic therapy might offset the responses
to GTN, participating in the loss of its effects on blood
pressure and heart rate. Our observations might explain why
interventions such as hydralazine failed to prevent this
“hemodynamic” (28), while being effective on “vascular,”
tolerance (29). Accordingly, blood pressure and heart rate
should not necessarily be considered accurate indexes of the
development of local processes that are believed to play a
relevant role in “vascular” tolerance (e.g., oxidative stress,
increased sensitivity to angiotensin II). The cause and effect
relationship between autonomic versus local vascular effects
of GTN in the development of tolerance has not yet been
investigated. However, it has been recently proposed that
increased angiotensin II and oxidative stress, and their
reciprocal enhancing effects, might be responsible for the
observed increase in sympathetic activity after sustained
nitrate exposure (30).
The clinical phenomenon of nitrate tolerance remains a
problem in a variety of settings. We believe that the present
observations extend our understanding of nitrate tolerance,
and might have direct clinical and methodological implica-
tions in this field.
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